Mechanisms of action of rapamycin in gliomas

Neuro-Oncology

Volumn 7, Issue 1, 2005, Pages 1-11

  Heimberger, Amy B ^a   Wang, Enze ^a   McGary, Eric C ^c   Hess, Kenneth R ^b   Henry, Verlene K ^a   Shono, Tadahisa ^a   Cohen, Zvi ^a   Gumin, Joy ^a   Sawaya, Raymond ^a   Conrad, Charles A ^b   Lang, Frederick F ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c Hilton Head Regional Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS; GELATINASE A; GELATINASE B; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERSTITIAL COLLAGENASE; PHOSPHATASE; PHOSPHATE BUFFERED SALINE; PROTEIN KINASE B; RAPAMYCIN; TENSIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CHROMOSOME 10; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOSTASIS; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; ENZYME INHIBITION; EXPERIMENTAL DESIGN; GENE DELETION; GLIOMA; IC 50; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; NULL ALLELE; OLIGODENDROGLIOMA; PROTEIN SYNTHESIS; SURVIVAL RATE; TREATMENT FAILURE; TUMOR CELL CULTURE; TUMOR CELL LINE; TUMOR REGRESSION; TUMOR XENOGRAFT; WESTERN BLOTTING; ZYMOGRAPHY;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLIOMA; HUMANS; IMMUNOHISTOCHEMISTRY; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICE; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHORIC MONOESTER HYDROLASES; PTEN PHOSPHOHYDROLASE; SIROLIMUS; TUMOR SUPPRESSOR PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 20044378096     PISSN: 15228517     EISSN: None     Source Type: Journal    
DOI: 10.1215/S1152851704000420     Document Type: Article

References (20)

1. Blouw, B., Song, H., Tihan, T., Bosze, J., Ferrara, N., Gerber, H.P., Johnson, R.S., and Bergers, G. (2003) The hypoxic response of tumors is dependent on their microenvironment. Cancer Cell 4 133-146.
2. Brugarolas, J.B., Vazquez, F., Reddy, A., Sellers, W.R., and Kaelin, W.G., Jr. (2003) TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell 4, 147-158.
3. Dilling, M.B., Dias, P., Shapiro, D.N., Germain, G.S., Johnson, R.K., and Houghton, P.J. (1994) Rapamycin selectively inhibits the growth of childhood rhabdomyosarcoma cells through inhibition of signaling via the type I insulin-like growth factor receptor. Cancer Res. 54, 903-907.
4. El-Hashemite, N., Walker, V., Zhang, H., and Kwiatkowski, D.J. (2003) Loss of Tsc1 or Tsc2 induces vascular endothelial growth factor production through mammalian target of rapamycin. Cancer Res. 63, 5173-5177.
5. Eshleman, J.S., Carlson, B.L., Mladek, A.C., Kastner, B.D., Shide, K.L., and Sarkaria, J.N. (2002) Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy. Cancer Res. 62, 7291-7297.
6. Fang, J., Yan, L., Shing, Y., and Moses, M.A. (2001) HIF-1alpha-mediated up-regulation of vascular endothelial growth factor, independent of basic fibroblast growth factor, is important in the switch to the angiogenic phenotype during early tumorigenesis. Cancer Res. 61, 5731-5735.
7. Guba, M., von Breitenbuch, P., Steinbauer, M., Koehl, G., Flegel, S., Hornung, M., Bruns, C.J., Zuelke, C., Farkas, S., Anthuber, M., Jauch, K.W., and Geissler, E.K. (2002) Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: Involvement of vascular endothelial growth factor. Nat. Med. 8, 128-135.
8. Houchens, D.P., Ovejera, A.A., Riblet, S.M., and Slagel, D.E. (1983) Human brain tumor xenografts in nude mice as a chemotherapy model. Eur. J. Cancer Clin. Oncol. 19, 799-805.
9. Hudson, C.C., Liu, M., Chiang, G.G., Otterness, D.M., Loomis, D.C., Kaper, F., Giaccia, A.J., and Abraham, R.T. (2002) Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol. Cell Biol. 22, 7004-7014.
10. Lal, S., Lacroix, M., Tofilon, P., Fuller, G.N., Sawaya, R., and Lang, F.F. (2000) An implantable guide-screw system for brain tumor studies in small animals. J. Neurosurg. 92, 326-333.
11. Lang, F.F., Gilbert, M.R., Puduvalli, V.K., Weinberg, J., Levin, V.A., Yung, W.K., Sawaya, R., Fuller, G.N., and Conrad, C.A. (2002) Toward better early-phase brain tumor clinical trials: A reappraisal of current methods and proposals for future strategies. Neuro-Oncol. 4, 268-277.
12. Neshat, M.S., Mellinghoff, I.K., Tran, C., Stiles, B., Thomas, G., Petersen, R., Frost, P., Gibbons, J.J., Wu, H., and Sawyers, C.L. (2001) Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc. Natl. Acad. Sci. USA 98, 10314-10319.
13. Price, D.J., Grove, J.R., Calvo, V., Avruch, J., and Bierer, B.E. (1992) Rapamycin-induced inhibition of the 70-kilodalton S6 protein kinase. Science 257, 973-977.
14. Rooprai, H.K., Rucklidge, G.J., Panou, C., and Pilkington, G.J. (2000) The effects of exogenous growth factors on matrix metalloproteinase secretion by human brain tumour cells. Br. J. Cancer 82, 52-55.
15. Schuler, W., Sedrani, R., Cottens, S., Haberlin, B., Schulz, M., Schuurman, H.J., Zenke, G., Zerwes, H.G., and Schreier, M.H. (1997) SDZ RAD, a new rapamycin derivative: Pharmacological properties in vitro and in vivo. Transplantation 64, 36-42.
16. Sehgal, S.N., Baker, H., and Vézina, C. (1975) Rapamycin (AY-22,989), a new antifungal antibiotic, II. Fermentation, isolation and characterization. J. Antibiot. (Tokyo) 28, 727-732.
17. Supko, J.G., and Malspeis, L. (1994) Dose-dependent pharmacokinetics of rapamycin-28-N,N-dimethylglycinate in the mouse. Cancer Chemother. Pharmacol. 33, 325-330.
18. Treins, C., Giorgetti-Peraldi, S., Murdaca, J., Semenza, G.L., and Van Obberghen, E. (2002) Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase/target of rapamycin-dependent signaling pathway. J. Biol. Chem. 277, 27975-27981.
19. Tsuzuki, Y., Fukumura, D., Oosthuyse, B., Koike, C., Carmeliet, P., and Jain, R.K. (2000) Vascular endothelial growth factor (VEGF) modulation by targeting hypoxia-inducible factor-1alpha→ hypoxia response element→ VEGF cascade differentially regulates vascular response and growth rate in tumors. Cancer Res. 60, 6248-6252.
20. Zhang, D., and Brodt, P. (2003) Type 1 insulin-like growth factor regulates MT1-MMP synthesis and tumor invasion via PI 3-kinase/Akt signaling. Oncogene 22, 974-982.